New drug approvals for neglected diseases increased from 2.6 annually from 2002 to 2008 to five in 2009 to 2012, according to a report from the Tufts Center for the Study of Drug Development. "The trend in approvals is clearly going in the right direction, but annual R&D spending to treat neglected diseases has leveled off at $3 billion in total, after rising rapidly from 2000 to 2007, which is a cause of concern," said Joshua Cohen, an assistant professor and the study's lead investigator.

Related Summaries